ORGANIZERS:

HRVATSKO DRUŠTVO FARMAKOLOGA
CROATIAN PHARMACOLOGICAL SOCIETY

HDKFiT

HALMED

MEDRI

HELD UNDER THE AUSPICES OF:

ACADEMIA SCIENTIARUM ET ARTIUM CROATICA MDCCCLXI

10th Croatian Congress of Pharmacology

with International Participation

1st Croatian Congress of Clinical Pharmacology

with International Participation

September
22 – 25
2022
Opatija

PROGRAMME

CONGRESS VENUE

Amadria Park Grand Hotel 4 Opatijska Cvijeta

Viktora Cara Emina 6, 51410, Opatija

September 22 – 25, 2022

Registration desk: Conference Park 25/7, ground floor

Computer-assisted presentation and audio-visual equipment: Conference Park 25/7

Congress halls 1A, 1B, 1C: Conference Park 25/7, 1st floor

Poster display: Conference Park 25/7, ground floor

Exhibition: Conference Park 25/7, 1st floor

REFRESHMENTS AND LUNCH

Coffee break: Conference Park 25/7, 1st floor / Coffee and nonalcoholic drinks will be served during the Congress (September 22 – 25, 2022)

Lunch break: Villa Camellia, restaurant Camellia / Lunch will be served during the Congress (September 23 – 24, 2022)

SOCIAL PROGRAMME

Opening ceremony with Plenary lecture: Conference Park 25/7, Hall 1A, 1st floor (September 22, 2022)

Welcome reception: Villa Camellia, Oleandar hall (September 22, 2022)

Congress dinner: Hotel Royal, Royal hall (September 24, 2022)

Congress closing and farewell: Conference Park 25/7, Hall 1A, 1st floor (September 25, 2022)

CONGRESS OFFICIAL LANGUAGES

Croatian and English

PROFESSIONAL CONGRESS ORGANIZER

O-TOURS PCO d.o.o. | Gajeva 6/1, 10000 Zagreb
Tel: +385 1 4831 444 | Email: tatjana.koprtla@otours.hr

CONGRESS WEB SITES

https://events.otours.hr/FARMAKO2022
http://hdf-pharma.mef.hr/

Plenary lectures

P 1	Development of antibody approaches to target TDP-43 proteinopathy in ALS and dementia, Jean-Pierre Julien (Canada)
P 2	Pharmacological and immunological interventions targeting COVID-19 disease, Luka Čičin-Šain (Germany)
P 3	Transfusion strategies and cardiovascular outcomes following an acute myocardial infarction, Tabassome Simon (France), EPHAR lecture 2022
P 4	Pharmacogenomics for personalized medicine: From bench... to the drug label... to bedside, Julia Carolin Stingl (Germany)

Symposia

Symposia	Organiser	Title
S 01 Precongress symposium	Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)	Drug regulation
S 02	Melita Šalković-Petrišić, Jelena Osmanović Barilar (Zagreb)	Pharmacology of central and peripheral metabolism in neurodegenerative disorders
S 03	Vera Vlahović Palčevski (Rijeka), Milan Čižman (Ljubljana)	Rational antimicrobial drug use – antimicrobial stewardship
S 04	Ivana Šutej, Kristina Peroš (Zagreb)	Pharmacology in dental medicine – pandemic response
S 05	Suzana Mimica (Osijek)	The place of biologic and biosimilar drugs in current medicine practice
S 06	Dubravka Jurišić Eržen (Rijeka)	Modern approach to the treatment of diabetes and metabolic diseases – new challenges and opportunities

S 07	Dubravka Švob Štrac (Zagreb)	Recent findings in neuropsychopharmacology of mental disorders
S 08	Stjepko Pleština (Zagreb)	News in the treatment of malignant diseases
S 09	Mladen Boban (Split)	Pharmacological approaches to cardiometabolic disorders
S 10	Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)	GMP mini symposium
S 11	Predrag Sikirić (Zagreb)	BPC157
S 12	Viktorija Erdeljić Turk (Zagreb)	Immunopharmacology: from vaccines to immunotherapy
S 13	Renata Jurišić Grubešić, Marko Skelin (Rijeka)	Rational pharmacotherapy: the role of the pharmacist
S 14	Dinko Vitezić (Rijeka)	Rare diseases: opportunities and challenges in the treatment
S 15	Kristina Pilipović, Jasenka Mršić-Pelčić (Rijeka)	Novel insights into the function of glial cells in health and disease
S 16	Nada Božina (Zagreb)	Pharmacogenomics in personalised medicine: how far have we come and how far could we go?
S 17	Iveta Merćep (Zagreb)	Development of new medicines
S 18	Lidija Bach Rojecky, Ivica Matak (Zagreb)	Clostridial neurotoxins and their role in sensory and motor functions in the central nervous system
S 19	Marijan Klarica (Zagreb)	Symposium "Marin Bulat": The influence of interstitial and cerebrospinal fluid movement on the distribution of drugs, metabolites and biomarkers within the craniospinal space

Round tables

RT 01 **HALMED**
Vaccines against Covid-19 – lessons learned

RT 02 **Croatian Pharmacological Society**
Croatian programme for EuCP qualification

Popular lectures

PL 01/1 We have a cure for obesity: the use of liraglutide 6.0mg/ml in the treatment of obesity – Miličić D, Klobučar Majanović S

PL 01/2 Communication between gut microbiota and neurons: the toll-like story – Giron MC

PL 02/1 Chinese traditional medicine-music therapy – Zhao Simonić R, Simonić A

PL 02/2 Traditional chinese medicine (TCM) as a vital component of integrative medicine – Simonić A, Zhao Simonić R

Workshop

W 01 **HALMED**
Pharmacovigilance

Timetable of Congress activities

Thursday, September 22, 2022	
12:00-18:00	**Registration of Congress participants**
14:00-17:30	**Precongress symposium S 01**
S 01 Hall 1A	**DRUG REGULATION** Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)
	S 01/1 HALMED'S PAST ACHIVEMENTS AND FUTURE CHALLENGES – Lovrek Romčević M, Tomić S (Croatia)
	S 01/2 REVISION OF THE EU GENERAL PHARMACEUTICALS LEGISLATION – Uzeirbegović S, Lovrek Romčević M, Marušić Kontent G, Tomić S (Croatia)
	S 01/3 PHARMACOVIGILANCE UPDATE – Margan Koletić Ž, Tomić S (Croatia)
	Refreshments
	S 01/4 THE ROLE OF CLINICAL PHARMACOLOGISTS IN THE AUTHORISATION OF INNOVATIVE MEDICINES – Juričić Nahal D (Croatia)
	S 01/5 SPECIFICS AND TENDENCIES OF DRUG CONSUMPTION IN CROATIA IN THE LAST FIVE YEARS – Draganić P (Croatia)
	S 01/6 MANAGEMENT OF MEDICINES SHORTAGES – Cvek J, Kontek A, Bilandžija B (Croatia)
	S 01/7 MEDICINAL PRODUCT DATA STANDARDISATION – PRECONDITION FOR EFFICIENT DATA EXCHANGE BETWEEN ALL STAKEHOLDERS – Sudić D, Grčić Plečko S (Croatia)
18:00-18:45 Hall 1A	**Opening ceremony**
18:45-19:30	**Plenary lecture P 1** Chairperson: Jasenka Mršić-Pelčić (Croatia)
P1 Hall 1A	**DEVELOPMENT OF ANTIBODY APPROACHES TO TARGET TDP-43 PROTEINOPATHY IN ALS AND DEMENTIA – Jean-Pierre Julien (Canada)**
19:30-21:00	**Welcome reception**

Friday, September 23, 2022	
08.30-10:00	**Round table RT 01 / Symposium S 02 / Symposium S 03**
RT 01 Hall 1A	**VACCINES AGAINST COVID-19 – LESSONS LEARNED** Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)
	RT 01/1 VACCINES AGAINST COVID-19 – LESSONS LEARNED FROM SAFETY MONITORING – Mirošević Skvrce N (Croatia)
	RT 01/2 VACCINES DEVELOPMENT – LESSONS FROM THE COVID-19 PANDEMIC – Šlezak T (Croatia)
	RT 01/3 CHALLENGES OF VACCINES QUALITY ASSESSMENT IN THE CONTEXT OF PANDEMIC – Derganc D (Croatia)
S 02 Hall 1B	**PHARMACOLOGY OF CENTRAL AND PERIPHERAL METABOLISM IN NEURODEGENERATIVE DISORDERS** Chairpersons: Melita Šalković-Petrišić (Croatia), Jelena Osmanović Barilar (Croatia)
	S 02/1 INTRODUCTION TO METABOLIC AND OTHER NON-COGNITIVE PATHOLOGY IN NEURODEGENERATIVE DISORDERS – Šalković-Petrišić M (Croatia)
	S 02/2 CROSSTALK BETWEEN OXIDATIVE STRESS AND ABERRANT INSULIN SIGNALLING IN THE BRAIN: INSIGHTS FOR NEURODEGENERATION – Barone E (Italy)
	S 02/3 METABOLIC EFFECTS OF ACUTE CENTRAL INCRETIN RECEPTORS INHIBITION IN A RAT MODEL OF SPORADIC ALZHEIMER'S DISEASE – Osmanović Barilar J, Knezović A, Babić A, Homolak J, Šalković-Petrišić M (Croatia)
	S 02/4 GASTROINTESTINAL CHANGES IN THE RAT MODEL OF SPORADIC ALZHEIMER'S DISEASE – AN OPPORTUNITY FOR THERAPEUTIC INTERVENTION WITH D-GALACTOSE? – Homolak J, Joja M, Virag D, Babić Perhoč A, Knezović A, Osmanović Barilar J, Šalković-Petrišić M (Croatia)
	S 02/5 MODELLING OF PARKINSON'S DISEASE BY INTRASTRIATAL ADMINISTRATION OF A DIABETOGENIC COMPOUND – Knezović A, Osmanović Barilar J, Farkas V, Bagaric R, Virag D, Babić Perhoč A, Homolak J, Šalković-Petrišić M (Croatia)
S 03 Hall 1C	**RATIONAL ANTIMICROBIAL DRUG USE – ANTIMICROBIAL STEWARDSHIP** Chairpersons: Vera Vlahović Palčevski (Croatia), Milan Čižman (Slovenia)
	S 03/1 ECDC PERSPECTIVE ON ANTIMICROBIAL STEWARDSHIP (on-line) – Monnet D (ECDC)
	S 03/2 THE ROLE OF EDUCATION IN ANTIMICROBIAL STEWARDSHIP – Beović B (Slovenia)

	S 03/3 USE OF ANTIBIOTICS DURING PANDEMIC COVID-19 – Baršić B (Croatia)
10:00-10:30	**Coffee break**
10:30-11:15	**Plenary lecture P 2** Chairperson: Viktorija Erdeljić Turk (Croatia)
P 2 Hall 1A	**PHARMACOLOGICAL AND IMMUNOLOGICAL INTERVENTIONS TARGETING COVID-19 DISEASE – Luka Čičin-Šain (Germany)**
11:20-12:50	**Symposium S 04 / Symposium S 05 / Symposium S 06**
S 04 Hall 1A	**PHARMACOLOGY IN DENTAL MEDICINE – PANDEMIC RESPONSE** Chairpersons: Ivana Šutej (Croatia), Kristina Peroš (Croatia)
	S 04/1 PANDEMIC RESPONSE – ADJUSTMENT IN PHARMACOTHERAPY AND PRESCRIBING – Šutej I (Croatia)
	S 04/2 ORAL ANTISEPTICS AGAINST CORONAVIRUS – ARE THEY JUSTIFIED – Bašić K (Croatia)
	S 04/3 STRENGHTS AND LIMITATIONS OF COVID SALIVA TESTING – Peroš K (Croatia)
	S 04/4 SALIVA DIAGNOSTICS ON EVERYONE'S LIPS: COVID-19 TESTING AND BEYOND – Hofner M, Kegler U, Huber J, Krainer J, Klausberger M, Regele V, Dürkop M, Vierlinger K, Weinhäusel A, Noehammer C (Austria)
S 05 Hall 1B	**THE PLACE OF BIOLOGIC AND BIOSIMILAR DRUGS IN CURRENT MEDICINE PRACTICE** Chairperson: Suzana Mimica (Croatia)
	S 05/1 THE CHALLENGES OF BIOSMILAR DRUGS USE: 16 YEARS LATER – Mimica S (Croatia)
	S 05/2 ADVERSE REACTIONS TO BIOLOGICAL MEDICINES – Juričić Nahal D (Croatia)
	S 05/3 NOVEL BIOLOGICAL MEDICINAL PRODUCTS FOR THE TREATMENT OF MALIGNANT AND AUTOIMMUNE DISEASES – Arapović Džakula S (Croatia)
	S 05/4 BIOLOGIC DRUGS FOR THE TREAMENT OF COVID-19: CURRENT KNOWLEDGE AND CHALLENGES FOR THE FUTURE – Havidić A (Croatia)
S 06 Hall 1C	**MODERN APPROACH TO THE TREATMENT OF DIABETES AND METABOLIC DISEASES – NEW CHALLENGES AND OPPORTUNITIES** Chairperson: Dubravka Jurišić Eržen (Croatia)
	S 06/1 INCRETIN THERAPY: EFFECTS BEYOND GLYCEMIC CONTROL –Tičinović Kurir T (Croatia)

	S 06/2 SGLT2 INHIBITORS – MECHANISM OF CARDIO AND RENAL PROTECTION – Rahelić D (Croatia)
	S 06/3 PAST, PRESENT AND FUTURE OF INSULIN THERAPY – Jurišić Eržen D (Croatia)
	S 06/4 IMMUNE CHECKPOINT INHIBITOR MEDIATED ENDOCRINOPATHIES – Nazlić J (Croatia)
12:50-14:10	**Lunch**
14:10-15:10	**Poster session 1 with organized discussion**
15:10-16:40	**Symposium S 07 / Symposium S 08 / Symposium S 09**
S 07 Hall 1A	**RECENT FINDINGS IN NEUROPSYCHOPHARMACOLOGY OF MENTAL DISORDERS** Chairperson: Dubravka Švob Štrac (Croatia)
	S 07/1 INTRODUCTION: RECENT FINDINGS IN NEUROPSYCHOPHARMACOLOGY OF MENTAL DISORDERS – Švob Štrac D (Croatia)
	S 07/2 BENEFICIAL EFFECT OF ESTROGEN DERIVATES IN ALZHEIMER DISEASE: STUDIES IN MICE MODEL – Zelena D, Farkas S, Szabó A, Török B, Sólyomvári C, Fazekas CL, Bánrévi K, Correia P, Chaves T, Ábrahám I (Hungary)
	S 07/3 SIDE EFFECTS OF PSYCHOPHARMACS: RECOGNIZE, PREVENT, TREAT – Uzun S, Kozumplik O, Mimica N (Croatia)
	S 07/4 MULTIMODAL APPROACH TO THE DEPRESSION TREATMENT: FOCUS ON VORTIOXETINE – Nikolac Perković M, Dvojković A, Nedić Erjavec G, Mihaljević Peleš A, Vuksan Čusa B, Tudor L, Kušević Z, Konjevod M, Živković M, Jakšić N, Pivac N, Šagud M (Croatia)
	S 07/5 METABOLOMICS IN ALZHEIMER'S DISEASE AS A TOOL FOR BIOMARKER DISCOVERY AND EARLY DIAGNOSIS – Nedić Erjavec G, Nikolac Perković M, Uzun S, Barbas C, Pivac N (Croatia)
	S 07/6 EPIGENETIC, GENETIC AND EXPRESSION ANALYSIS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN ALZHEIMER'S DISEASE – Tudor L, Nikolac Perković M, Babić Leko M, Videtič Paska A, Kouter K, Miloš T, Nedić Erjavec G, Vuić B, Konjevod M, Šimić G, Borovečki F, Pivac N (Croatia)
S 08 Hall 1B	**NEWS IN THE TREATMENT OF MALIGNANT DISEASES** Chairperson: Stjepko Pleština (Croatia)
	S 08/1 ONCOLOGY DURING THE DEVELOPMENT OF PERSONALIZED MEDICINE – Pleština S (Croatia)

	S 08/2 MOLECULAR TUMOR PROFILE IN THE ERA OF PRECISION MEDICINE – THE EXAMPLE OF CHOLANGIOCELLULAR CARCINOMA – Belev B (Croatia)
	S 08/3 ANTIBODY DRUG CONJUGATES IN THE TREATMENT OF METASTATIC BREAST CANCER – Dedić Plavetić N (Croatia)
	S 08/4 IMMUNE CHECKPOINT INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS – THE MECHANISMS, EFFICACY, AND SAFETY OF ICI AGENTS AND COMBINATIONS – Pleština S (Croatia)
S 09 Hall 1C	**PHARMACOLOGICAL APPROACHES TO CARDIOMETABOLIC DISORDERS** Chairperson: Mladen Boban (Croatia)
	S 09/1 CHANGES IN THE MYOCARDIAL METABOLISM IN TYPE 2 DIABETES MELLITUS – Ljubkovic M, Bulat C, Ćavar M, Grkovic I, Lemaire C, Marinovic J (Croatia)
	S 09/2 ANTIDIABETICS IN CARDIOVASCULAR DISEASE THERAPY – Knežević A (Croatia)
	S 09/3 WINE CONSUMPTION IN TYPE 2 DIABETES MELLITUS: FRIEND OR FOE – Boban M (Croatia)
	S 09/4 HEPCIDIN: A NEW SITE OF ACTION OF WINE IN PATIENTS WITH DIABETES MELLITUS TYPE 2 – Gujinović D (Croatia)
	S 09/5 EFFECT OF MODERATE WHITE WINE CONSUMPTION ON THE EXPRESSION OF HSP70, GPX, CAT AND NQO1 IN RAT CARDIOMYOCYTES – Benzon B, Mastelić A, Grahovac M, Matijević J, Marinović Ljubković J, Ljubković M, Mudnić I, Grković I, Boban M (Croatia)
16:40-17:00	**Coffee break**
17:00-17:45	**Plenary lecture P 3** Chairperson: Dinko Vitezić (Croatia)
P 3 Hall 1A	**TRANSFUSION STRATEGIES AND CARDIOVASCULAR OUTCOMES FOLLOWING AN ACUTE MYOCARDIAL INFARCTION – Tabassome Simon (France),** EPHAR lecture 2022
17:50-18:20 Hall 1A	**Annual HDF Assembly (for HDF members only)**

Saturday, September 24, 2022	
08:30-10:00	**Symposium S 10 / Symposium S 11 / Symposium S 12**
S 10 Hall 1A	**GMP MINI SYMPOSIUM** Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)
	S 10/1 INSPECTION OD GOOD MANUFACTURING PRACTICE – Kolonić T, Bencetić Marijanović M (Croatia)
	S 10/2 SERIOUS GMP NON-COMPLIANCE – Hodak Lj (Croatia)
	S 10/3 CROSS-CONTAMINATION RISKS IN PHARMACEUTICAL PRODUCTION, GMP PERSPECTIVE – Jukić S (Croatia)
	S 10/4 IMPORTATION, QUALITY CONTROL AND BATCH RELEASE OF MEDICINAL PRODUCTS – Trbojević Krpanić T (Croatia)
S 11 Hall 1B	**BPC157** Chairperson: Predrag Sikirić (Croatia)
	S 11/1 GASTRIC PENTADECAPEPTIDE BPC 157 IN CYTOPROTECTION TO RESOLVE MAJOR VESSEL OCCLUSION DISTURBANCES, ISCHEMIA-REPERFUSION INJURY – Sikirić P (Croatia)
	S 11/2 THE NEUROLEPTICS, AMPHETAMINE AND DOMPERIDONE APPLICATION AS INNATE VASCULAR FAILURE, AND THE STABLE GASTRIC PENTADECAPEPTIDE BPC 157, AS THERAPY, MIGHT BE THE PARTICULAR KEY – Strbe S (Croatia)
	S 11/3 STABLE GASTRIC PENTADECAPEPTIDE BPC 157 AND MUSCLE HEALING FOR POSSIBLE THERAPY – Skrtic A (Croatia)
	S 11/4 THE HEARTH DISTURBANCES, MYOCARDIAL INFARCTION, ARRHYTHMIAS, CONGESTIVE HEART FAILURE, PULMONARY HYPERTENSION AND THROMBOSIS PRESENTATION FOR THE STABLE GASTRIC PENTADECAPEPTIDE BPC 157 AS USEFUL PEPTIDE THERAPY – Seiwerth S (Croatia)
S 12 Hall 1C	**IMMUNOPHARMACOLOGY: FROM VACCINES TO IMMUNOTHERAPY** Chairperson: Viktorija Erdeljić Turk (Croatia)
	S 12/1 NEW THERAPIES FOR IMMUNE-MEDIATED DISEASES – Mimica S (Croatia)
	S 12/2 TARGETED THERAPIES FOR ALLERGIC DISEASES – Čegec I (Croatia)
	S 12/3 DEVELOPMENT OF IMMUNO-ONCOLOGY DRUGS – Erdeljić Turk V (Croatia)

	S 12/4 VACCINES: PREVENTIVE, THERAPEUTIC, PERSONALIZED – Macolić- Šarinić V (EMA)
	S 12/5 IMMUNE-MEDIATED ADVERSE EFFECTS OF COVID-19 VACCINE – Strikić D, Erdeljić Turk V (Croatia)
10:00-10:30	**Coffee break**
10:30-12:00	**Symposium S 13 / Popular lectures PL 01 / Popular lectures PL 02**
S 13 Hall 1A	**RATIONAL PHARMACOTHERAPY: THE ROLE OF THE PHARMACIST** Chairpersons: Renata Jurišić Grubešić (Croatia), Marko Skelin (Croatia)
	S 13/1 THE FUTURE OF THE CENTRAL PREPARATION OF ANTINEOPLASTIC DRUGS IN THE ERA OF DIGITIZATION AND ROBOTIZATION – Pavlica V (Croatia)
	S 13/2 RATIONAL PHYTOTHERAPY IN THE MAINTENANCE OF MENTAL HEALTH – Vladimir-Knežević S (Croatia)
	S 13/3 POTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PEOPLE – LESSONS LEARNED FROM EUROAGEISM PROJECT – Ortner Hadžiabdić M (Croatia)
	S 13/4 COMPREHENSIVE MEDICATION MANAGEMENT AT THE PRIMARY CARE LEVEL – IMPLEMENTATION AT THE HEALTH CARE CENTRE ZAGREB CENTRE – Mucalo I, Brajković A (Croatia)
	S 13/5 INFLUENCE OF QUALITY OF LIFE ON ADHERENCE TO ADJUVANT ENDOCRINE THERAPY IN WOMEN WITH EARLY BREAST CANCER – Dugonjić Okroša A, Silovski T, Dedić Plavetić N, Mucalo I (Croatia)
	S 13/6 RATIONAL DRUG USE IN A PATIENT WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASES – A CASE STUDY – Mucalo I, Bićanić LA, Brajković A (Croatia)
PL 01 Hall 1B	**Popular lectures PL 01** Chairperson: Goran Hauser (Croatia)
10:30-11:00	**PL 01/1** WE HAVE A CURE FOR OBESITY: THE USE OF LIRAGLUTIDE 6.0MG/ML IN THE TREATMENT OF OBESITY – Miličić D, Klobučar Majanović S (Croatia)
11:00-11:30	**PL 01/2** COMMUNICATION BETWEEN GUT MICROBIOTA AND NEURONS: THE TOLL-LIKE STORY – Giron MC (Italy)
PL 02 Hall 1C	**Popular lectures PL 02** Chairperson: Kristina Pilipović (Croatia)
10:30-11:00	**PL 02/1** CHINESE TRADITIONAL MEDICINE-MUSIC THERAPY – Zhao Simonić R, Simonić A (Croatia)

11:00-11:30	**PL 02/2** TRADITIONAL CHINESE MEDICINE (TCM) AS A VITAL COMPONENT OF INTEGRATIVE MEDICINE – Simonić A, Zhao Simonić R (Croatia)
12:00-12:45	**Plenary lecture P 4** Chairperson: Nada Božina (Croatia)
P 4 Hall 1A	**PHARMACOGENOMICS FOR PERSONALIZED MEDICINE: FROM BENCH... TO THE DRUG LABEL... TO BEDSIDE – Julia Carolin Stingl (Germany)**
12:45-14:00	**Lunch**
14:00-15:00	**Poster session 2 with organized discussion**
15:00-16:30	**Workshop W 01 / Symposium S 14 / Symposium S 15**
W 01 Hall 1A	**PHARMACOVIGILANCE** Agency for Medicinal Products and Medical Devices (HALMED, Zagreb)
	W 01/1 MEDICATION ERRORS IN CHILDREN AND ADOLESCENTS – Mirošević Skvrce N, Margan Koletić Ž, Prpić S (Croatia)
S 14 Hall 1B	**RARE DISEASES: OPPORTUNITIES AND CHALLENGES IN THE TREATMENT** Chairperson: Dinko Vitezić (Croatia)
	S 14/1 ORPHAN DRUGS: FROM RESEARCH TO APPLICATION – Vitezić D (Croatia)
	S 14/2 EUROPEAN INITIATIVES IN A COMPREHENSIVE APPROACH TO THE TREATMENT OF RARE DISEASES – Barišić I (Croatia)
	S 14/3 AVAILABILITY OF ORPHAN MEDICINES IN CROATIA – Strbad T (Croatia)
	S 14/4 FROM DIAGNOSIS TO TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS TYPE 2 (CLN2) – CLINICAL AND ADMINISTRATIVE CHALLENGES – Prpić I (Croatia)
	S 14/5 REAL-WORLD EVALUATION OF PHARMACOLOGICAL TREATMENT FOR SPINAL MUSCULAR ATROPHY – CROATIAN EXPERIENCE – Belančić A, Strbad T, Vitezić D (Croatia)
S 15 Hall 1C	**NOVEL INSIGHTS INTO THE FUNCTION OF GLIAL CELLS IN HEALTH AND DISEASE** Chairpersons: Kristina Pilipović (Croatia), Jasenka Mršić-Pelčić (Croatia)
	S 15/1 INTRODUCTION – BRAIN INJURY: NEUROPROTECTIVE STRATEGIES – Mršić-Pelčić J (Croatia)
	S 15/2 DRUG REPURPOSING MODEL: NEURO-IMMUNO-METABOLIC ROLE OF NALTREXONE – Kučić N, Rački V, Grahovac I, Mršić-Pelčić J (Croatia)

	S 15/3 THE EFFECTS OF CHEMICALLY-FUNCTIONALIZED SINGLE-WALLED CARBON NANOTUBES ON PRIMARY MOUSE ASTROCYTES IN AN IN VITRO MODEL OF SEVERE TRAUMATIC BRAIN INJURY – Pilipović K, Gržeta N, Harej Hrkać A, Parpura V (Croatia)
	S 15/4 IMMUNITY IN AMYOTROPHIC LATERAL SCLEROSIS: BLURRED LINES BETWEEN EXCESSIVE INFLAMMATION AND INEFFICIENT IMMUNE RESPONSES – Munitić I (Croatia)
	S 15/5 TRAUMATIC BRAIN INJURY AND PIOGLITAZONE: BENEFITS AND LIMITATIONS OF NEUROPROTECTIVE THERAPY – Dolenec P, Pilipović K, Delač Lj, Slavić A, Župan Ž, Župan G (Croatia)
	S 15/6 EFFECTS OF A SINGLE MODERATE TRAUMATIC BRAIN INJURY IN MOUSE ON THE TAR DNA-BINDING PROTEIN 43 AND ITS CONNECTION WITH NEUROINFLAMMATION AND SYNAPTIC PLASTICITY – Janković T, Gržeta N, Rajič Bumber J, Dolenec P, Križ J, Župan G, Pilipović K (Croatia)
16:30-17:00	**Coffee break**
17:00-18:30	**Symposium S 16 / Symposium S 17 / Symposium S 18**
S 16 Hall 1A	**PHARMACOGENOMICS IN PERSONALISED MEDICINE: HOW FAR HAVE WE COME AND HOW FAR COULD WE GO?** Chairperson: Nada Božina (Croatia)
	S 16/1 PHARMACOGENOMICS IN ADVERSE DRUG REACTIONS LEADING TO EMERGENCY HOSPITAL VISITS – Stingl JC (Germany)
	S 16/2 PRECISION MEDICINE IN RENAL TRANSPLANT PATIENTS – ROLE OF ABCG2 LOSS OF FUNCTION POLYMORPHISM – Borić Bilušić A, Božina N, Lalić Z, Nađ -Škegro S, Penezić L, Barišić K, Trkulja V (Croatia)
	S 16/3 PHARMACOGENOMICS IN THE PREDICTION OF CARDIOVASCULAR DRUGS ADVERSE REACTIONS – PGX-CARDIODRUG: PRELIMINARY RESULTS – Božina T, Vrkić Kirhmajer M, Šimičević L, Ganoci L, Palić J, Bićanić LA, Mucalo I, Samardžić J (Croatia)
	S 16/4 INFLUENCE OF ABCG2 421C>A POLYMORPHISM AND VALPROATE ON STEADY-STATE DISPOSITION OF LAMOTRIGINE – Šušak Sporiš I, Božina N, Trkulja V, Klarica Domjanović I, Sporiš D, Bašić S, Marković I, Lovrić M, Čolak Romić Z (Croatia)
S 17 Hall 1B	**DEVELOPMENT OF NEW MEDICINES** Chairperson: Iveta Merćep (Croatia)
	S 17/1 CLINICAL TRIALS AND THE NEW EUROPEAN UNION DIRECTIVE – Merćep I, Strikić D (Croatia)
	S 17/2 DRUG DEVELOPMENT – Radačić Aumiler M (Croatia)

	S 17/3 WHY DO CLINICAL DRUG TRIALS SO OFTEN FAIL? – Makar-Aušperger K (Croatia)
	S 17/4 IN SILICO METHODS IN DEVELOPMENT OF NEW THERAPEUTIC COMPOUNDS – Likić R (Croatia)
	S 17/5 INTERPRETING RESULTS OF CLINICAL TRIALS: COMMON STATISTICAL CONCERNS – Erdeljić Turk V (Croatia)
S 18 Hall 1C	**CLOSTRIDIAL NEUROTOXINS AND THEIR ROLE IN SENSORY AND MOTOR FUNCTIONS IN THE CENTRAL NERVOUS SYSTEM** Chairpersons: Lidija Bach Rojecky (Croatia), Ivica Matak (Croatia)
	S 18/1 BOTULINUM TOXIN TYPE AXONAL TRANSPORT FROM THE PERIPHERY TO THE BRAIN: IS IT GOOD OR BAD? – Lacković Z (Croatia)
	S 18/2 CORTICAL REWIRING FOLLOWING PERIPHERAL INJECTION OF BOTULINUM TOXIN TYPE A – Tiberi A, Massa V, Pirazzini M, Rossetto O, Caleo M, Restani L (Italy)
	S 18/3 FABS FROM PURIFIED HUMABS OPEN TO THE INTRATHECAL THERAPY OF TETANUS – Pirazzini M, Fabris F, Šoštarić P, Meglić P, Tonellato M, Grinzato A, Corti D, Lanzavechhia A, Schiavo G, Rossetto O, Zanotti G, Montecucco C, Matak I (Italy)
	S 18/4 LONG TERM CENTRAL EFFECTS OF BOTULINUM TOXIN TYPE A ON MUSCULAR FUNCTION AND RECOVERY IN RAT – Šoštarić P, Matić M, Matak I (Croatia)
	S 18/5 UPDATE ON BOTULINUM TOXIN TYPE A CENTRAL ACTION ON PAIN – ARE THE PRIMARY AFFERENTS IN THE SPINAL CORD ITS FINAL DESTINATION? – Vađunec D, Matak I, Bach-Rojecky L (Croatia)
20:00	**Congress dinner**

Sunday, September 25, 2022	
09:00-10:15	**Round table RT 02**
RT 02 Hall 1A	**CROATIAN PROGRAMME FOR EuCP QUALIFICATION** Croatian Pharmacological Society Moderators: Vladimir Trkulja, Melita Šalković Petrišić, Jasenka Mršić-Pelčić, Mladen Boban, Dubravka Švob Štrac, Jelena Osmanović Barilar
10:15-11:15	**Poster session 3 with organized discussion: Students section "HDF youth programme"**
11:15-11:30	**Coffee break**
11:30-13:00	**Symposium S 19**
S 19 Hall 1A	**SYMPOSIUM "MARIN BULAT" – THE INFLUENCE OF INTERSTITIAL AND CEREBROSPINAL FLUID MOVEMENT ON THE DISTRIBUTION OF DRUGS, METABOLITES AND BIOMARKERS WITHIN THE CRANIOSPINAL SPACE** Chairperson: Marijan Klarica (Croatia)
	S 19/1 DISTRIBUTION OF VARIOUS SUBSTANCES BETWEEN CSF AND INTERSTITIAL SPACE AFTER THEIR APPLICATION IN DIFFERENT CSF COMPARTMENTS – Klarica M, Radoš M, Jurjević I, Orešković D (Croatia)
	S 19/2 DYNAMICS OF BLOOD AND CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE – Šimić G, Babić Leko M, Mihelčić M (Croatia)
	S 19/3 SUBSTANCE DISTRIBUTION CHANGES AFTER CSF PATHWAY IMPAIREMENT IN DIFFERENT PARTS OF CRANIOSPINAL SPACE – Klarica M, Radoš M, Jurjević I, Kudelić N, Orešković D (Croatia)
	S 19/4 ROLE OF ARACHNOID GRANULATIONS IN CEREBROSPINAL FLUID PHYSIOLOGY: ANALYSIS BY MAGNETIC RESONANCE IMAGING – Radoš M, Živko M, Periša A, Orešković D, Klarica M (Croatia)
13:00-13:15 Hall 1A	**Best poster awards**
13:15-14:00 Hall 1A	**Closing ceremony**

Poster sections

Friday, September 23, 2022

Poster session 1 with organized discussion

Chairpersons: Suzana Mimica (Croatia), Dubravka Švob Štrac (Croatia)

P1 01	PHARMACOGENOMICS OF ROSUVASTATIN – IMPACT OF ABCG2 AND SLCO1B1 POLYMORPHISMS AND DRUG-DRUG INTERACTIONS ON DEVELOPMENT OF ADVERSE DRUG REACTIONS – Ganoci L, Mucalo I, Bićanić LA, Palić J, Šimičević L, Vrkić Kirhmajer M, Samardžić J, Božina T
P1 02	RHABDOMYOLYSIS IN KIDNEY TRANSPLANT PATIENT WITH COVID-19: POSSIBLE ROLE OF REMDESIVIR AND ATORVASTATIN DRUG-DRUG-GENE INTERACTIONS – Fištrek Prlić M, Osmanović Barilar J, Ganoci L, Šimičević L, Božina N
P1 03	THE ROLE OF PHARMACOGENETICS AS POSSIBLE RISK FACTOR FOR RIVAROXABAN - ASSOCIATED BLEEDING – Šimičević L, Slišković AM, Vrkić Kirhmajer M, Ganoci L, Holik H, Samardžić J, Božina T
P1 04	ASSOCIATION OF PERIOD CIRCADIAN GENES WITH CHEMORESISTANCE OF COLON CANCER CELLS WITH BRAFV600E MUTATION – Markova-Car EP, Ripić M, Sedić M
P1 05	CONSUMPTION OF ALLERGY MEDICINE IN EUROPE, 2017-2020: IS THERE A SIMILAR PATTERN OF ALLERGY MEDICINE CONSUMPTION IN THREE EUROPEAN COUNTRIES? – Pelčić G, Draganić P, Rožmanić V, Ragulj M
P1 06	ORAL CHALLENGE WITH TRIMETHOPRIM-SULFAMETHOXAZOLE IN A PATIENT WITH ALLERGY IN DRUG HISTORY – Čagalj Z, Mimica S, Havidić A
P1 07	NOVEL AGENTS IN DYSLIPIDAEMIA THERAPY – ARE WE SWITCHING DAILY TREATMENT TO WEEKLY OR EVEN MONTHLY? – Strikić D, Slišković AM, Merćep I
P1 08	KNOWLEDGE, ATTITUDES AND AWARENESS REGARDING FOOD-DRUG INTERACTIONS AMONG PHARMACISTS IN CROATIA – Pavičić Žeželj S, Kenđel Jovanović G, Mašković S, Skočibušić N, Belančić A, Rubinić I, Vlahović-Palčevski V
P1 09	PHYTOCHEMICAL ANALYSIS AND PHYTOTHERAPEUTIC POTENTIAL OF SELECTED *VERONICA* L. SPECIES (PLANTAGINACEAE) FROM CROATIA – Jurišić Grubešić R, Molc N, Nazlić M, Kremer D, Juretić L, Dunkić V

P1 10	IMPACT OF PHARMACIST-LED MEDICATION MANAGEMENT ON ADVERSE DRUG REACTIONS REPORTED BY ELDERLY CARDIOVASCULAR PATIENTS AT A PRIMARY CARE LEVEL – Strgačić M, Pupačić A, Nalo L, Brajković A, Mucalo I
P1 11	THE ASSESSMENT OF SALIVARY PARAMETERS IN OBSTRUCTIVE SLEEP APNEA PATIENTS AFTER CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT: A 6-MONTH FOLLOW-UP STUDY – Tranfić M, Pecotić R, Lušić Kalcina L, Pavlinac Dodig I, Valić M, Rogić D, Lapić I, Grdiša K, Peroš K, Đogaš Z
P1 12	METHODS OF DETERMINATION OF PROGESTERONE AND ESTRADIOL IN SALIVA – Smajli Vokshi K, Peroš K
P1 13	EFFECT OF CALCIUM PRETREATMENT ON ENAMEL FLOURIDE REACTIVITY AND IN REMINERALIZATION DEMINERALIZATION PROCESSES – Kullashi Spahija F, Peroš K
P1 14	DYSTONIA IN EUROPE: A SURVEY TOWARDS DIAGNOSIS AND THERAPY FROM A PATIENTS' PERSPECTIVE – Relja M, Dressler D, Albanese A, Morgante F, Trkulja V
P1 15	ASPARAGINASE ACTIVITY IN ALL TREATMENT – Lovrić M, Glasovac D, Jelić M, Ščavničar A, Bilić E, Rogić D
P1 16	THE EFFECTS OF PROLONGED ANTISEPTIC USE DURING COVID-19 PANDEMIC ON SKIN PARAMETERS – Modun D, Bročić I, Mićanović M, Bukić J, Rušić D, Šešelja Perišin A, Leskur D
P1 17	NON-INTERVENTIONAL PILOT STUDY EVALUATING THE EFFICACY AND SAFETY OF LYSOZYMEBASED THERAPY IN PATIENTS WITH NON-INFECTIOUS SORE THROAT – Karakaš S, Huduti DZ, Mehic M, Šukalo A, Dzananovic Jaganjac J, Tanovic Avdic A, Skopljak A, Dupovac A, Sarajlic Z, Glamoclija U, Limo S
P1 18	THE EFFECTS OF TOPICAL APPLICATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON THE CONCENTRATION OF IMMUNE PARAMETERS IN A MODEL OF COLLAGEN-INDUCED ARTHRITIS – RESEARCH PLAN – Maleškić Kapo S, Rakanović-Todić M, Burnazović-Ristić L, Loga-Zec S, Kusturica J, Limo S, Kulo Ćesić A
P1 19	NO FEAR TO EXPLORE THE UNSAFE WITH CEFTRIAXONE! – Tvrdeić A, Miše B, Babacanli A, Poljak LJ
P1 20	ELEVATED C MAZE – TO TEST OR NOT TO TEST IN THE MORNING? – Tvrdeić A, Miše B, Babacanli A, Poljak LJ
P1 21	COX-2 RS689466 POLYMORPHISM AND METABOLIC SYNDROME-RELATED PARAMETERS AMONG MEDICATED SCHIZOPHRENIA PATIENTS – Zatković L, Nadalin S, Dević Pavlić S, Peitl V, Karlović D, Rebić J, Buretić-Tomljanović A

P1 22	THE EFFECTS OF MODERATE RED WINE CONSUMPTION ON ARTERIAL STIFFNESS AND HEMODYNAMIC PARAMETERS IN TYPE 2 DIABETES MELLITUS – Mudnić I, Nazlić J, Boban Z, Gujinović D, Dželalija AM, Boban M
P1 23	THE PROTECTIVE ACTIONS OF DHEA/S AND BDNF IN AN IN VITRO MODEL OF PARKINSON'S DISEASE – Miloš T, Vuić B, Bacelj N, Nedić Erjavec G, Tudor L, Konjevod M, Švob Štrac D, Nikolac Perković M
P1 24	MOLECULAR MECHANISMS OF THE RENAL EFFECT OF EMPAGLIFLOZIN ON LLC-PK1 CELLULAR MODEL OF DIABETIC NEPHROPATHY – Mihaljević V, Omanović Kolarić T, Smolić M, Kuna L, Kizivat T, Petrović A, Smolić R, Včev A, Bilić Ćurčić I
P1 25	EFFECTS OF DIFFERENT DOSES OF PIOGLITAZONE ON NEURONAL DAMAGE, INFLAMMATION AND MOTOR PERFORMANCE FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT – Dolenec P, Pilipović K, Župan Ž, Župan G
P1 26	CHARACTERIZATION OF ASTROCYTIC RESPONSE TO EXPOSURE TO CHEMICALLY FUNCTIONALIZED SINGLE-WALLED CARBON NANOTUBES IN AN IN VITRO STRECH INJURY MODEL – Harej Hrkać A, Gržeta N, Mladenić T, Jurički I, Parpura V, Pilipović K
P1 27	THE EFFECTS OF REPETITIVE MILD TRAUMATIC BRAIN INJURY ON SOME PROTEINOPATHY SUSCEPTIBLE PROTEINS IN THE MOUSE FRONTAL CORTEX – Janković T, Gržeta N, Rajič Bumber J, Dolenec P, Križ J, Župan G, Pilipović K
P1 28	THE ROLE OF CLINICAL PHARMACOLOGIST IN ASSESSMENT OF CONTRAINDICATIONS FOR VACCINATION AGAINST COVID-19 – Strujić E, Pastović M, Petrinović M, Mimica S
P1 29	PROCEDURES AT SUSPECTED HYPERSENSITIVITY TO LOCAL ANESTHETICS – Petrinović M, Strujić E, Pastović M, Mimica S

Saturday, September 24, 2022

Poster session 2 with organized discussion

Chairpersons: Kristina Pilipović (Croatia), Pero Draganić (Croatia), Viktorija Erdeljić Turk (Croatia)

P2 01	NEUROPROTECTIVE ACTIONS OF DHEA AND DHEAS IN PRIMARY MOUSE NEURONS AND SHSY5Y CELLS EXPOSED TO TOXIC AMYLOID BETA OLIGOMERS – Vuić B, Miloš T, Nikolac Perković M, Nedić Erjavec G, Tudor L, Konjevod M, Pivac N, Švob Štrac D
P2 02	OVER-DOSE CAFFEINE TOXICITY IN RATS AND TRETMENT WITH STABLE GASTRIC PENTADECAPEPTIDE BPC 157 – Vukovic V, Sablic M, Krezic I
P2 03	THE ASSOCIATION OF PLATELET SEROTONIN (5-HT) AND 5HT2A GENE POLYMORPHISMS WITH ASTHMA – Konjevod M, Sreter K, Popovic-Grle S, Lampalo M, Jukic I, Bingulac-Popovic J, Safic Stanic H, Markeljevic J, Pivac N, Svob Strac D
P2 04	THE EFFECTS OF PHLORIDZIN, A SODIUM-GLUCOSE COTRANSPORTER INHIBITOR IN AN ORAL GALACTOSE-TREATED RAT MODEL OF SPORADIC ALZHEIMER'S DISEASE – Babić Perhoč A, Homolak J, Knezović A, Osmanović Barilar J, Virag D, Šalković-Petrišić M
P2 05	ANTISTEATOTIC EFFECT OF LIRAGLUTIDE IS MEDIATED THROUGH ACSL1 and SREBP-1c SIGNALING PATHWAY IN A CELL CULTURE MODEL OF TAMOXIFEN-INDUCED STEATOSIS – Omanović Kolarić T, Ninčević V, Kizivat T, Kuna L, Zjalić M, Bilić-Ćurčić I, Smolić R, Roguljić H, Petrović A, Včev A, Wu G, Smolić M
P2 06	IS VASCULAR RESPONSIVENESS OF THE ISOLATED RAT AORTA AFFECTED BY 4 WEEKS OF MODERATE STANDARD AND MACERATED WHITE WINE CONSUMPTION? – Mornar M, Filipović N, Grahovac M, Gujinović D, Dželalija AM, Grković I, Boban M, Mudnić I
P2 07	AWARENESS AND ATTITUDES OF NURSES ABOUT DIET THERAPY AND NUTRITIONAL SUPPORT OF PERSONS WHIT CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN HOSPITAL ENVIROMENT – Kocić Z, Fistonić T, Jovanović Ž
P2 08	PREVALENCE OF ANXIOLYTICS USE BY HEALTH PROFESSIONALS – Jovanović Ž, Pešut S, Kocić Z
P2 09	PATIENTS ATTITUDES TOWARDS ANTIPSYCHOTIC MEDICATION: A CROSS-SECTIONAL STUDY – Bukic J, Rusic D, Leskur D, Šešelja Perisin A, Herceg D, Cohadzic T, Modun D, Herceg M
P2 10	DO FINAL-YEAR MEDICAL STUDENTS IN CROATIA FEEL SUFFICIENTLY PREPARED TO PRESCRIBE ANTIMICROBIALS PRUDENTLY? – COMPARISON BETWEEN FOUR CROATIAN MEDICAL SCHOOLS – Belančić A, Palčevski D, Likić R, Vlahović-Palčevski V

P2 11	EFFECTS OF LOW DOSE TETANUS TOXIN INJECTIONS INTO THE RAT MOTOR CORTEX AND BASAL GANGLIA ON MOTOR PERFORMANCE – Meglić P, Šoštarić P, Virag D, Matak I
P2 12	EXPERIMENTAL FOCAL MUSCLE HYPERTONIA OFFERS NOVEL INSIGHTS INTO MOTOR EFFECTS OF BOTULINUM TOXIN TYPE A – Matak I, Meglić P, Šoštarić P
P2 13	TETANUS NEUROTOXIN ACTS AT THE NEUROMUSCULAR JUNCTION AND ON BRAINSTEM CENTERS THAT CONTROL MUSCLE MOVEMENT, RESPIRATION AND SWALLOWING IN A MURINE MODEL OF CEPHALIC TETANUS – Fabris F, Varani S, Tonellato M, Matak I, Šostaric P, Meglic P, Simonato M, Rubini A, Caleo M, Megighian A, Rossetto O, Montecucco C, Pirazzini M
P2 14	CALCIUM CHLORIDE-INDUCED RAT MODEL OF ABDOMINAL AORTIC ANEURYSM AND THE EFFECT OF PENTADECAPEPTIDE BPC 157 – Zizek H, Sjekavica I, Smoday I, Oroz K, Boban Blagaic A
P2 15	BRAIN EDEMA AND BLOOD PRESSURE DISTURBANCES INDUCED BY ACUTE WATER INTOXICATION IN A RAT MODEL AND THE EFFECT OF PENTADECAPAPTIDE BPC 157 – Yago H, Zizek H, Smoday IM, Durasin T
P2 16	TREATMENT OF ULCER, INTRACRANIAL, PORTAL AND CAVAL HYPERTENSION AND AORTAL HYPOTENSION WITH BPC 157 AFTER STOMACH PERFORATION – Vranes H, Kalogjera L, Chiddenton MH, Buric S
P2 17	STABLE GASTRIC PENTADECAPEPTIDE BPC 157 THERAPY EFFECT ON REPERFUSION FOLLOWING MAINTAINED INTRA-ABDOMINAL HYPERTENSION, GRADE III AND IV – Tepes M, Madzar Z, Miskic B, Miskic S, Duzel A, Sever M, Dretar V
P2 18	BPC 157 IN PSORIASIS MODEL – Šola M, Skroza N, Mangino G, Boban Blagaic A
P2 19	THERAPEUTIC EFFECT OF BPC 157 ON MANDIBULAR FRACTURE HEALING – Suman O, Staresinic M, Kocman I, Jadrijevic S
P2 20	PENTADECAPEPTIDE BPC 157 AS THERAPY OF THE INFERIOR CAVAL VEIN EMBOLIZATION POST-EMBOLIZATION SYNDROME WITH SODIUM LAURATE IN RATS – Smoday IM, Kalogjera L, Buric S, Vranes H
P2 21	THERAPY EFFECT OF THE PENTADECAPEPTIDE BPC 157 ON DEVELOPMENT OF ABDOMINAL AORTIC ANEURYSM AND VASCULAR FAILURE SYNDROME CAUSED BY CIPROFLOXACIN – Skorak I, Brizic I, Hriberski K, Krezić I, Žižek H, Smoday IM, Meštrović T, Pavić P, Sikirić P
P2 22	THE EFFECT OF PENTADECAPEPTIDE BPC 157 ON ALCOHOL- INDUCED LESIONS OF BREAST AND SOURROUNDING TISSUE IN RATS – Samara M, Zic R, Sikiric P
P2 23	„OCCLUSION-LIKE" SYNDROME IN RAT LOWER LEG FRACTURE AND THE THERAPEUTIC EFFECT OF PENTADECAPEPTIDE BPC 157 – Prtoric A, Dobric I, Jurjevic I, Durasin T

P2 24	SOTALOL-INDUCED GENERAL OCCLUSION-LIKE SYNDROME AND QTC PROLONGATION IN RATS ARE COUNTERACTED BY PENTADECAPEPTIDE BPC 157 – Premuzic Mestrovic I, Smoday IM, Mestrovic T, Skorak I, Haluzan D, Figl J, Brizic I, Staresinic M, Pavic P
P2 25	PROTECTIVE EFFECTS OF PENTADECAPEPTIDE BPC 157 ON CAUSTIC LESIONS OF THE ESOPHAGUS IN RATS – Peklic M, Krezic I, Boban Blagaic A, Vranes H, Smoday IM
P2 26	TOURNIQUET-INDUCED COMPARTMENT SYNDROME OF RATS' LIMB AND ITS COUNTERACTION WITH PENTADECAPEPTIDE BPC 157 THERAPY – Oroz K, Coric L, Dretar V
P2 27	BPC 157 COUNTERACTS RADIATION-INDUCED ORAL MUCOSITIS IN RATS – Milatic K, Alajbeg I, Sobat H, Andabak-Rogulj A, Reić T
P2 28	CYTOPROTECTIVE EFFECTS OF BPC 157 ON MULTIORGAN DAMAGE CAUSED BY HIGH DOSES OF MEGESTROL ACETATE IN RATS – Krtalic B, Koprivanac A, Kalogjera L, Oroz K, Durasin T
P2 29	NEUROPROTECTIVE EFFECT OF PENTADEKAPEPTIDE BPC 157 ON 3-NITRO PROPRIONIC ACID-INDUCED MODEL OF HUNTINGTONS DISEASE – Krezic I, Jurjevic I, Chiddenton HM
P2 30	EFFECT OF PENTADECAPEPTIDE BPC 157 ON LUNG REEXPANSION IN RIGHT-SIDED PNEUMOTHORAX IN RATS WITH PENETRATING CHEST INJURY – Koprivanac A, Krtalic I, Zizek H, Boban Blagaic A, Oroz K, Coric L
P2 31	STABLE GASTRIC PENTADECAPEPTIDE BPC 157 THERAPY EFFECT ON REPERFUSION FOLLOWING OCCLUSION OF SUPERIOR MESENTERIC ARTERY, SUPERIOR MESENTERIC VEIN, AND SUPERIOR MESENTERIC ARTERY AND VEIN – Knezevic M, Knezevic T, Kolak T, Prtoric A, Sever M, Giljanovic A, Gojkovic S, Muzinic D, Boban Balagaic A
P2 32	PENTADECAPEPTIDE BPC 157 AS THERAPY OF THE AIR EMBOLIZATION AND POST-EMBOLIZATION SYNDROME IN RATS – Kalogjera L, Smoday I, Chiddenton HM, Buric S, Coric L
P2 33	EFFECT OF PENTADECAPEPTIDE BPC 157 ON APICAL PERIODONTITIS CAUSED BY PULP EXPOSURE IN RATS – Juzbasic M, Talapko J, Krezic I, Zizek H, Tomas M
P2 34	SYNDROME ARISING AFTER CATALEPTOGENIC DOSE OF L-NAME APPLICATION IN RATS AND THE EFFECT OF PENTADECAPEPTIDE BPC 157 – Jurca I, Zizek H, Sjekavica I, Coric L
P2 35	THERAPEUTIC EFFECT OF PENTADECAPEPTIDE BPC157 ON KREON INDUCED MODEL OF ABDOMINAL AORTA ANEURYSM IN RATS – Hriberski K, Brizic I, Skorak I, Haluzan D, Figl J, Pavic P, Mestrovic T
P2 36	OCCLUSION OF SUPERIOR SINUS SAGITTAL SINUS IN RATS AND THERAPY WITH THE STABLE GASTRIC PENTADECAPEPTIDE BPC 157, L-NAME AND L-ARGININE – Gojkovic S, Dretar V, Krezic I

P2 37	FOURIER TRANSFORM INFRARED SPECTROSCOPY MEASUREMENTS OF INFLUENCE OF THE STABLE GASTRIC PENTADECAPEPTIDE BPC 157 ON RAT THORACIC AORTA – Gamulin O, Maria Krajacic M, Skrabic M, Oroz K, Coric H
P2 38	INFLUENCE OF PENTADECAPEPTIDE BPC 157 ON THE HEALING OF COLON-COLONIC ANASTOMOSIS UNDER VENOUS CONGESTION CONDITIONS IN RATS – Duzel A, Artukovic B, Rakic M, Kolovrat M, Begovic A, Andabak M, Sabic A
P2 39	THE EFFECT OF PENTADECAPEPTIDE BPC 157 ON GLYCEROL INDUCED ACUTE KIDNEY INJURY – Dretar V, Durasin T, Vranes H
P2 40	THE EFFECT OF BPC-157 ON SURGICALLY INDUCED LUMBAR SPINE INSTABILITY IN A RAT MODEL – Dokuzovic S, Krezic I, Smoday IM, Durasin T, Dretar V
P2 41	PILOCARPINE AND LITHIUM STATUS EPILEPTICUS IN RATS AND PENTADECAPEPTIDE BPC 157, L-NAME, AND L-ARGININE THERAPY EFFECT – Chiddenton HM, Buric S, Kalogjera L, Vranes H
P2 42	THERAPEUTIC EFFECT OF PENTADECAPEPTIDE BPC 157 IN RATS WITH ISCHEMIA-REPERFUSION INJURY AFTER OCCLUSION OF THE INFRARENAL ABDOMINAL AORTA – Brižić I, Škorak I, Hriberski K, Pavić P, Meštrović T, Krezić I, Žižak H, Sikirić P
P2 43	SEVERE ULCERATIVE COLITIS AND PENTADECAPEPTIDE BPC 157 THERAPY – Bekic D, Kalogjera L, Vranes HS
P2 44	THE EFFECT OF BPC-157 ON THE SISTEMIC EFFFECTS OF INDUCED OPEN ANGLE GLAUCOMA IN RAT MODEL – Sablic M, Vukovic V, Kokot A

Sunday, September 25, 2022

Poster session 3 with organized discussion: Students section "HDF youth programme"

Chairpersons: Petra Dolenec (Croatia), Jelena Osmanović Barilar (Croatia)

P3 01	THE EFFECT OF MUSIC AND SOUNDS ON ANXIETY AND STRESS LEVELS – Bacelj N, Tudor L
P3 02	SAFETY PROFILE OF JAK INHIBITORS BASED ON THE RECEIVED REPORTS OF SUSPECTED SIDE EFFECTS – Pavlinovic L, Mirošević Skvrce N
P3 03	ATTITUDES TOWARDS USE OF SUPPLEMENTS DURING COVID- 19 PANDEMICS – Matijević A, Mimica S
P3 04	THE EFFECT OF ORAL GALACTOSE ON THE INSULIN SIGNALLING PATHWAY IN THE PARIETAL CORTEX OF A TRANSGENIC MICE MODEL OF ALZHEIMER'S DISEASE – Ipša A, Babić Perhoč A
P3 05	USE OF CANNABIS FOR MEDICINAL PURPOSES – Valković F, Mršić-Pelčić J
P3 06	REDOX HOMEOSTASIS PRESERVATION ALONG THE GASTROINTESTINAL TRACT OF THE RAT BRAIN-FIRST 6-HYDROXYDOPAMINE MODEL OF PARKINSON'S DISEASE – Grabarić G, Homolak J, Šalković-Petrišić M
P3 07	ADHERENCE TO CHRONIC THERAPY DURING COVID-19 PANDEMICS – Balić I, Mimica S
P3 08	INTESTINAL REDOX PARAMETERS IN THE ALZHEIMER'S DISEASE RATS RECEIVING ORAL D-GALACTOSE – Joja M, Homolak J, Šalković-Petrišić M
P3 09	ASSESSMENT OF PATIENTS ON ORAL ANTITHROMBOTIC THERAPY REFERRED TO THE DEPARTMENT OF ORAL SURGERY FOR SIMPLE TOOTH EXTRACTION – A PRELIMINARY REPORT – Burja Vladić M, Salarić I, Zdunić E, Perić B, Vuletić L
P3 10	COMPLEX MECHANISMS OF BOTULINUM TOXIN TYPE A ACTION ON EXPERIMENTAL PAIN -TIME TO LOOK BEYOND THE FIRST SYNAPSE – Mustapić M, Skenderović M, Vađ unec D, Bach-Rojecky L
P3 11	BIOCHEMICAL PROPERTIES OF RAT FECAL PELLETS ACCOMPANYING THE DEVELOPMENT OF MOTOR DEFICITS IN A 6-HYDROXYDOPAMINE-INDUCED RAT MODEL OF PARKINSON'S DISEASE – Marković P, Babić Perhoč A
P3 12	THE NEUROPROTECTIVE POTENTIAL OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AN *IN VITRO* MODEL OF ALZHEIMER'S DISEASE – Pendelić R, Nedić Erjavec G

P3 13	ANTIBIOTIC THERAPY IN THE COVID-19 PANDEMIC: RETROSPECTIVE COHORT STUDY OF PATIENTS HOSPITALIZED AT THE UNIVERSITY HOSPITAL OF SPLIT – Starčević D, Pranić S, Pinjatela J, Skelin M, Mudnić I
P3 14	EXPLORATION OF THE ANTIOXIDATIVE AND ANTI-INFLAMMATORY EFFECTS OF ARONIA MELANOCARPA EXTRACT IN AN *IN VITRO* MODEL OF PARKINSON'S DISEASE – Glavan T, Harej Hrkać A, Pilipović K
P3 15	TESTING THE POSSIBILITY OF LOADING AND SUBSEQUENT RELEASE OF FLUORIDE IONS FROM BIOACTIVE DENTAL MATERIALS AFTER COATING WITH HIGHLY CONCENTRATED FLUORIDE GEL – Kelić M, Kilić D, Peroš K

MSD

INVENTING FOR LIFE

HR-NON-00120 EXP: 02/24

RECARBRIO®

(imipenem, cilastatin, relebaktam) za infuziju 1,25 g

MSD

Merck Sharp & Dohme d.o.o.
Ivana Lučića 2a, 10000 Zagreb, Hrvatska,
tel.: +385 1 66 11 333; fax: +385 1 66 11 350
Izrađeno u Hrvatskoj, studeni, 2020.
Sva prava pridržana.
HR-TIX-00001 EXP 11/2022

Samo za zdravstvene djelatnike.
Prije propisivanja lijeka Recarbrio®, molimo pročitajte zadnji odobreni sažetak opisa svojstava lijeka i uputu o lijeku odobrene u RH.
Broj odobrenja za stavljanje lijeka u promet: EU/1/19/1420/001
Datum prvog odobrenja za Recarbrio®: 13. veljače 2020.
Datum revizije teksta za Recarbrio®: 16. studenoga, 2020.
Režim izdavanja lijeka: na recept, u ljekarni

novo nordisk®

Novo Nordisk Hrvatska d.o.o. - Ulica D.T. Gavrana 17 - 10020 Zagreb, Hrvatska
HR22OB00007 Datum sastavljanja: 3/2022.

AstraZeneca
what science can do

is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter@AstraZeneca.

AstraZeneca

AstraZeneca d.o.o., Radnička cesta 80, 10000 Zagreb, Tel: +385 1 4628 000; www.astrazeneca.com
HR-2491, rujan 2022., vrijedi do 09/2023.

We are leading a revolution in oncology to redefine cancer care

AstraZeneca

SAMO ZA ZDRAVSTVENE RADNIKE

Veeva ID: HR-1949, 02/2022., vrijedi do 02/2023.

AstraZeneca d.o.o., Radnička cesta 80, 10 000 Zagreb
Tel: +385 1 4628 000; www.astrazeneca.com

Lilly

RECORDATI RARE DISEASES

GROUP

BIOMARIN®

EU-BMRN-00029 May 2022

Selvita

GASI ŽGARAVICU!



POGODAN I ZA TRUDNIČKE ŽGARAVICE

Reflustat sadrži natrijev alginat koji ima:

- prirodno porijeklo
- djelovanje u roku nekoliko minuta
- dugotrajno olakšanje simptoma

JGL Obitelj

jgl

KAKO SPRIJEČITI KARDIOVASKULARNE BOLESTI?

ZNA OLI - VAŠ VIRTUALNI ASISTENT U KOMUNIKACIJI S PACIJENTIMA

HR220908557 08.09.2022.

Oli

SVE O KARDIOVASKULARNOM ZDRAVLJU NA JEDNOME MJESTU – POUZDANE INFORMACIJE I SAVJETI ZA OČUVANJE ZDRAVLJA I BOLJE ISHODE LIJEČENJA

NOVARTIS

abbvie

Copyright © 2022 Takeda Pharmaceutical Company Limited. Sva prava pridržana.
Takeda i logotip Takeda su zaštitni znaci tvrtke Takeda Pharmaceutical Company Limited, koji se koriste pod licencom.

Takeda Pharmaceuticals Croatia d.o.o.
Ivana Lučića, 10000 Zagreb, Hrvatska
tel.: 01/377 88 96, faks: 01/375 76 88,
www.takeda.com

SAMO ZA ZDRAVSTVENE RADNIKE.
C-APROM/HR/OG/0001
Datum pripreme: kolovoz, 2022.

LJEKARNA
Nives Miloš

Zajedno do zdravlja

GOLD SPONSORS

MSD INVENTING FOR LIFE

novo nordisk®

AstraZeneca

SILVER SPONSORS

Lilly

RECORDATI RARE DISEASES GROUP

BRONZE SPONSORS

BIOMARIN

Selvita

jgl

NOVARTIS

SPONSORS

ALKALOID Health above all

abbvie

ewo pharma since 1958

DONORS

Swixx BioPharma Modern Medicines for All

LJEKARNA ZUBOVIĆ

LJEKARNA Nives Miloš

SUPORTED BY

KEFO

Pfizer

Takeda

TURISTIČKA ZAJEDNICA KVARNERA

OPATIJA

MINISTARSTVO ZNANOSTI I OBRAZOVANJA REPUBLIKE HRVATSKE

EPHAR

450
400
350
300
250
200
150
100
500
500